Article Text

Download PDFPDF
PWE-104 A Randomised Double-Blind Placebo-Controlled Trial of A Multi-Strain Probiotic in The Treatment of Chronic Symptoms Post Diverticulitis
  1. C Kvasnovsky1,
  2. AN Donaldson2,
  3. R Sherwood3,
  4. I Bjarnason4,
  5. S Papagrigordiasis4
  1. 1Department of Surgery, University of Maryland Medical Centre, Baltimore
  2. 2Applied Mathematics and Statistics, State University of New York, Stoney Brook, United States
  3. 3Clinical Biochemistry
  4. 4Colorectal Surgery, King’s College Hospital, London, UK


Introduction The emergency treatment for acute diverticulitis is straightforward, but many patients develop post-diverticulitis chronic symptoms which resemble that of Irritable Bowel Syndrome (IBS). We assessed the possible effect of Symprove, a multi strain probiotic, on these symptoms in a randomised double-blind placebo-controlled trial.

Methods This was a single-centre, randomised, double-blind, placebo-controlled trial of the efficacy of the probiotic Symprove in adult patients with post-diverticulitis IBS like symptoms. 143 patients were randomly assigned to receive 1 mL/kg/day of the probiotic (N = 72) or placebo (N = 71) for 3 months. The primary endpoint was a change in abdominal pain. Secondary endpoints included nine abdominal symptoms and changes in faecal calprotectin.

Results 120 patients completed the trial. Pain score with the probiotic decreased from 9.5±7.7 to 5.9±6.7, which did not differ significantly (P = 0.12) with that of placebo (7.5±7.0 to 6.1±6.4).

The probiotic improved constipation, diarrhoea, mucorrhoea, back pain and vaginal discharge significantly (p < 0.04) above that of placebo, but not abdominal pain, PR bleeding, dysuria or bloating. Symprove prevented an increase in intestinal inflammation in male patients (p = 0.05)

Conclusion The probiotic Symprove did not improve abdominal pain scores significantly, but significantly improved some other post-diverticulitis symptoms and prevented an escalation in intestinal inflammatory activity in male patients.

Disclosure of Interest C. Kvasnovsky: None Declared, A. Donaldson: None Declared, R. Sherwood: None Declared, I. Bjarnason Grant/research support from: Received financial support for a SpR for a PhD student (Charlotte), S. Papagrigordiasis Grant/research support from: Recipent of a grant from Symprove for a PhD studentship (Charlotte)

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.